Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jong-Mu Sun

Showing results (141-150 of 303) with videos related to

Pageof 31
Sort By:
European Journal of Cancer (Oxford, England : 1990)|May 2, 2022
Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancerSehhoon Park, Jae Myoung Noh, Yoon-La Choi, et al.
Future Oncology (London, England)|May 2, 2024
LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinomaJong-Mu Sun, Antoine Adenis, Peter C Enzinger, et al.
Practical Radiation Oncology|April 22, 2026
The implication of failure patterns after neoadjuvant chemoradiotherapy with small involved field in esophageal squamous cell carcinomaHyunju Shin, Dongryul Oh, Jae Myoung Noh, et al.
Journal of Medical Internet Research|August 27, 2021
Feasibility of an Interactive Health Coaching Mobile App to Prevent Malnutrition and Muscle Loss in Esophageal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy: Prospective Pilot StudyKyungmi Yang, Dongryul Oh, Jae Myoung Noh, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2025
A matching-adjusted indirect comparison of first-line lorlatinib and alectinib for the treatment of ALK-rearranged advanced non-small cell lung cancerJoo-Young Byun, Jinyong Kim, Sehhoon Park, et al.
International Journal of Cancer|February 27, 2019
Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary diseaseSun Hye Shin, Hye Yun Park, Yunjoo Im, et al.
Head & Neck|October 2, 2014
Presence of anaplastic lymphoma kinase translocation in sarcomatoid carcinoma of head and neck and treatment effect of crizotinib: A case seriesSung Min Kim, Moon Jin Kim, Hyun Ae Jung, et al.
Journal for Immunotherapy of Cancer|February 14, 2023
Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatmentHyunsu Kim, Sehhoon Park, Kyoung-Yeon Han, et al.
Pharmacogenomics|April 1, 2015
Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patientsHye In Woo, Jung A Kim, Hyun Ae Jung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2018
Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II TrialJinhyun Cho, Hae Su Kim, Bo Mi Ku, et al.
Pageof 31

Showing results (141-150 of 303) with videos related to

Sort By:
Pageof 31
European Journal of Cancer (Oxford, England : 1990)|May 2, 2022
Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancerSehhoon Park, Jae Myoung Noh, Yoon-La Choi, et al.
Future Oncology (London, England)|May 2, 2024
LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinomaJong-Mu Sun, Antoine Adenis, Peter C Enzinger, et al.
Practical Radiation Oncology|April 22, 2026
The implication of failure patterns after neoadjuvant chemoradiotherapy with small involved field in esophageal squamous cell carcinomaHyunju Shin, Dongryul Oh, Jae Myoung Noh, et al.
Journal of Medical Internet Research|August 27, 2021
Feasibility of an Interactive Health Coaching Mobile App to Prevent Malnutrition and Muscle Loss in Esophageal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy: Prospective Pilot StudyKyungmi Yang, Dongryul Oh, Jae Myoung Noh, et al.
European Journal of Cancer (Oxford, England : 1990)|September 27, 2025
A matching-adjusted indirect comparison of first-line lorlatinib and alectinib for the treatment of ALK-rearranged advanced non-small cell lung cancerJoo-Young Byun, Jinyong Kim, Sehhoon Park, et al.
International Journal of Cancer|February 27, 2019
Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary diseaseSun Hye Shin, Hye Yun Park, Yunjoo Im, et al.
Head & Neck|October 2, 2014
Presence of anaplastic lymphoma kinase translocation in sarcomatoid carcinoma of head and neck and treatment effect of crizotinib: A case seriesSung Min Kim, Moon Jin Kim, Hyun Ae Jung, et al.
Journal for Immunotherapy of Cancer|February 14, 2023
Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatmentHyunsu Kim, Sehhoon Park, Kyoung-Yeon Han, et al.
Pharmacogenomics|April 1, 2015
Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patientsHye In Woo, Jung A Kim, Hyun Ae Jung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2018
Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II TrialJinhyun Cho, Hae Su Kim, Bo Mi Ku, et al.
Pageof 31